Acarix AB (publ) (ACARIX.ST)
SEK 0.25
(-4.05%)
SEK 0.25
(-4.05%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 82.85 Million SEK | 2.16% |
| 2022 | 81.09 Million SEK | 48.75% |
| 2021 | 54.51 Million SEK | 26.71% |
| 2020 | 43.02 Million SEK | -10.13% |
| 2019 | 47.87 Million SEK | 10.74% |
| 2018 | 43.23 Million SEK | 38.68% |
| 2017 | 31.17 Million SEK | 16.36% |
| 2016 | 26.79 Million SEK | 299.67% |
| 2015 | 6.7 Million SEK | 31.72% |
| 2014 | 5.08 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 16.34 Million SEK | -29.04% |
| 2024 Q2 | 17.64 Million SEK | 12.41% |
| 2023 Q4 | 23.02 Million SEK | 24.36% |
| 2023 FY | 82.85 Million SEK | 2.16% |
| 2023 Q2 | 23.18 Million SEK | 27.95% |
| 2023 Q3 | 18.51 Million SEK | -20.14% |
| 2023 Q1 | 18.12 Million SEK | -24.32% |
| 2022 Q2 | 19.69 Million SEK | 24.66% |
| 2022 FY | 81.09 Million SEK | 48.75% |
| 2022 Q1 | 15.8 Million SEK | -6.73% |
| 2022 Q4 | 23.94 Million SEK | 10.58% |
| 2022 Q3 | 21.65 Million SEK | 9.92% |
| 2021 FY | 54.51 Million SEK | 26.71% |
| 2021 Q2 | 13.72 Million SEK | 12.36% |
| 2021 Q3 | 11.63 Million SEK | -15.2% |
| 2021 Q4 | 16.94 Million SEK | 45.57% |
| 2021 Q1 | 12.21 Million SEK | 0.94% |
| 2020 Q3 | 9.44 Million SEK | -10.78% |
| 2020 FY | 43.02 Million SEK | -10.13% |
| 2020 Q4 | 12.1 Million SEK | 28.18% |
| 2020 Q2 | 10.58 Million SEK | -2.96% |
| 2020 Q1 | 10.9 Million SEK | 2.96% |
| 2019 Q3 | 11.4 Million SEK | -11.23% |
| 2019 Q4 | 10.59 Million SEK | -7.1% |
| 2019 FY | 47.87 Million SEK | 10.74% |
| 2019 Q1 | 13.03 Million SEK | 5.77% |
| 2019 Q2 | 12.84 Million SEK | -1.49% |
| 2018 Q1 | 8.17 Million SEK | -34.18% |
| 2018 FY | 43.23 Million SEK | 38.68% |
| 2018 Q4 | 12.32 Million SEK | -5.15% |
| 2018 Q3 | 12.99 Million SEK | 33.44% |
| 2018 Q2 | 9.73 Million SEK | 19.2% |
| 2017 Q1 | 3.93 Million SEK | -75.69% |
| 2017 Q2 | 7.11 Million SEK | 80.78% |
| 2017 Q3 | 7.71 Million SEK | 8.54% |
| 2017 FY | 31.17 Million SEK | 16.36% |
| 2017 Q4 | 12.41 Million SEK | 60.85% |
| 2016 Q3 | 6.99 Million SEK | 184.54% |
| 2016 Q1 | 2.29 Million SEK | 202.24% |
| 2016 FY | 26.79 Million SEK | 299.67% |
| 2016 Q4 | 16.18 Million SEK | 131.34% |
| 2016 Q2 | 2.45 Million SEK | 7.15% |
| 2015 Q4 | 759 Thousand SEK | 0.0% |
| 2015 FY | 6.7 Million SEK | 31.72% |
| 2014 FY | 5.08 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ADDvise Group AB (publ) | 611.8 Million SEK | 86.458% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 86.458% |
| Arcoma AB | 53.25 Million SEK | -55.581% |
| Bactiguard Holding AB (publ) | 4.96 Million SEK | -1567.337% |
| BICO Group AB (publ) | 2.84 Billion SEK | 97.091% |
| Boule Diagnostics AB (publ) | 210.44 Million SEK | 60.631% |
| CellaVision AB (publ) | 295.99 Million SEK | 72.009% |
| Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | -20.194% |
| Chordate Medical Holding AB (publ) | 1.3 Million SEK | -6228.374% |
| C-Rad AB (publ) | 3.8 Million SEK | -2080.263% |
| Duearity AB (publ) | 21.58 Million SEK | -283.831% |
| Dignitana AB (publ) | 74.73 Million SEK | -10.857% |
| Episurf Medical AB (publ) | 2.7 Million SEK | -2968.519% |
| Getinge AB (publ) | 10.75 Billion SEK | 99.23% |
| Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | -354.507% |
| Iconovo AB (publ) | 63.35 Million SEK | -30.772% |
| Integrum AB (publ) | 90.57 Million SEK | 8.525% |
| Luxbright AB (publ) | 23.09 Million SEK | -258.805% |
| Mentice AB (publ) | 237.06 Million SEK | 65.051% |
| OssDsign AB (publ) | 175.6 Million SEK | 52.819% |
| Paxman AB (publ) | 133.8 Million SEK | 38.079% |
| Promimic AB (publ) | 48.55 Million SEK | -70.642% |
| Qlife Holding AB (publ) | 162.38 Million SEK | 48.979% |
| SciBase Holding AB (publ) | 69.97 Million SEK | -18.398% |
| ScandiDos AB (publ) | 61.03 Million SEK | -35.735% |
| Sectra AB (publ) | 39.06 Million SEK | -112.093% |
| Sedana Medical AB (publ) | 174.52 Million SEK | 52.529% |
| Senzime AB (publ) | 141.51 Million SEK | 41.456% |
| SpectraCure AB (publ) | 12.12 Million SEK | -583.13% |
| Stille AB | 87.21 Million SEK | 5.009% |
| Vitrolife AB (publ) | 5.56 Billion SEK | 98.512% |
| Xvivo Perfusion AB (publ) | 440.92 Million SEK | 81.21% |